Andersen 1974.

Methods	Allocation: randomly assigned (described on Andersen 1972 preliminary results), no further details. Blindness: double (commercial preparations but administered by people not involved in the trial). Design: 2 parallel groups. Duration: 3 months. Analysis: intention‐to‐treat not performed in the trial. Country: Sweden.
Participants	Diagnosis: schizophrenia or paranoid syndrome.** N=40. Age: range 21‐65 years. Sex: M 19, F19. Setting: hospital. History: chronic patients. Inclusion: hospitalisation < 10 years, no organic disorders, no substance abuse, no depression episodes, no violent patients.
Interventions	1. Trifluoperazine: range 3‐12 mg/bid (mean 4.34 mg). N=20. 2. Pimozide: range 3‐14 mg/day (mean 3.92 mg). N=20.
Outcomes	Side effects. Use of antiparkinson agents. Leaving the study early. Unable to use ‐ Mental state: (scale ‐ 'p' values only). Behaviour: (Wing behaviour scale ‐ 'p' values only). Side effects: (point rating scale ‐ validity unknown).
Notes	** Mixed diagnosis.
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment?	Unclear risk	B ‐ Unclear